
Entrada Therapeutics (TRDA) | Stock Overview & Key Data
Entrada Therapeutics Performance Comparison
Stock Range
Today's Range
52 Week Range
All-Time High: $36.85 on November 15, 2021
Explore how other US stocks compare to their 52-week ranges: View US Market 52-Week Insights
Key Statistics
Financial Highlights
Profitability
Returns and Earnings
Growth
Peer Performance Comparison
Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y |
---|---|---|---|---|---|---|---|---|---|
Entrada Therapeutics TRDA | 271.75M Small-cap | -6.50% | -18.16% | -13.89% | -53.86% | -61.28% | -55.86% | -30.17% | -66.37% |
Vertex VRTX | 124.20B Large-cap | 4.33% | 6.20% | 0.85% | 17.08% | 18.18% | -2.00% | 63.56% | 62.62% |
Regeneron REGN | 59.14B Large-cap | 2.27% | 6.92% | 2.45% | -19.68% | -21.73% | -49.77% | -9.05% | -14.20% |
Cg Oncology CGON | 1.98B Small-cap | 0.78% | -1.35% | 53.77% | -10.23% | -6.42% | -23.64% | -22.81% | -22.81% |
Belite Bio BLTE | 1.94B Small-cap | 4.30% | 1.37% | 6.00% | 11.83% | -4.22% | 30.51% | 52.51% | 105.64% |
Disc Medicine IRON | 1.93B Small-cap | 5.94% | 9.29% | 64.63% | -2.09% | -7.13% | 18.42% | 19.36% | -82.16% |
Ownership & Short Interest
Entrada Therapeutics Recurring Investment / Dollar-Cost Averaging Calculator
Calculate how a regular investment in Entrada Therapeutics would have performed over time.
Note: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing.
Frequently Asked Questions
What is TRDA's 52-week high and low?
In the last 52 weeks, Entrada Therapeutics reached a high of $21.79 (on December 9, 2024) and a low of $6.59 (on July 1, 2025).
What is the market cap and P/E ratio for TRDA?
Curious about Entrada Therapeutics's size and valuation? Its market capitalization stands at 271.75M. When it comes to valuation, the P/E ratio (trailing twelve months) is 12.34, and the forward P/E (looking ahead) is -2.27.
Does TRDA pay dividends? If so, what's the yield?
As for dividends, Entrada Therapeutics isn't currently offering a significant yield, or that specific data isn't available right now.
Who are Entrada Therapeutics's main competitors or similar companies to consider before investing?
When looking at Entrada Therapeutics, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company | Mkt Cap | Sector | Industry | 1Y Return | 3Y Return |
---|---|---|---|---|---|
Vertex VRTX | 124.20B | Healthcare | Biotechnology | -2.00% | 63.56% |
Regeneron REGN | 59.14B | Healthcare | Biotechnology | -49.77% | -9.05% |
Cg Oncology CGON | 1.98B | Healthcare | Biotechnology | -23.64% | -22.81% |
Belite Bio BLTE | 1.94B | Healthcare | Biotechnology | 30.51% | 52.51% |
Disc Medicine IRON | 1.93B | Healthcare | Biotechnology | 18.42% | 19.36% |
For a more comprehensive list, please see the Peer Performance Comparison table on this page.
What are the key financial health indicators for Entrada Therapeutics Inc.? (e.g., ROE, Debt/Equity)
To get a sense of Entrada Therapeutics's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is 7.22%, the Debt to Equity ratio from the most recent quarter is 13.66, and its Gross Profit Margin stands at N/A.
What is the recent revenue and earnings growth for TRDA?
Looking at Entrada Therapeutics's growth, its revenue over the trailing twelve months (TTM) was $172M. Compared to the same quarter last year (YoY), quarterly revenue grew by -65.20%, and quarterly earnings saw a YoY growth of -65.23%.
How much of TRDA stock is held by insiders and institutions?
Wondering who owns Entrada Therapeutics stock? Company insiders (like executives and directors) hold about 12.36% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 80.10%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.